Loading mutual fund details…
WhiteOak Capital Pharma and Heathcare Fund Regular Plan Growth is an equity scheme managed by WhiteOak Capital Mutual Fund. It has ranked in the top half of its category for 1 of the last 1 reported years. Risk-adjusted return (Sharpe ratio) is 0.00. The total expense ratio is 2.57% on assets of ₹603Cr. The fund is currently managed by Ms. Trupti Agarwal, appointed within the last year.
Lower is better.
This scheme classifies as Large-Blend on the 3x3 equity style box, with 87% of its portfolio classified as of 2026-05-29.
| Holding | Sector |
|---|
| Window | Min | P25 | Median |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Same fund, monthly SIPs over rolling 1/3/5-year windows.
| Scheme | AMC | AUM | TER | 3Y |
|---|
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| Weight |
|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Healthcare | 10.47% |
| JB Chemicals & Pharmaceuticals Limited | Healthcare | 6.54% |
| LAURUS LABS LIMITED | Healthcare | 4.13% |
| FORTIS HEALTHCARE LIMITED. | Healthcare | 4.12% |
| APOLLO HOSPITALS ENTERPRISE LIMITED | Healthcare | 4.02% |
| GLENMARK PHARMACEUTICALS LIMITED | Healthcare | 3.41% |
| AUROBINDO PHARMA LIMITED | Healthcare | 3.33% |
| MAX HEALTHCARE INSTITUTE LIMITED | Healthcare | 3.31% |
| Krishna Institute Of Medical Sciences Limited | Healthcare | 3.13% |
| Sai Life Sciences Limited | Healthcare | 3.02% |
| LUPIN LIMITED | Healthcare | 2.97% |
| NEULAND LABORATORIES LIMITED | Healthcare | 2.64% |
| CORONA REMEDIES PRIVATE LIMITED | Healthcare | 2.43% |
| THYROCARE TECHNOLOGIES LIMITED | Healthcare | 1.98% |
| NARAYANA HRUDAYALAYA LIMITED | Healthcare | 1.93% |
| EMCURE PHARMACEUTICALS LIMITED | Healthcare | 1.83% |
| AJANTA PHARMA LIMITED | Healthcare | 1.78% |
| AETHER INDUSTRIES LIMITED | Basic Materials | 1.56% |
| NAVIN FLUORINE INTERNATIONAL LTD | Basic Materials | 1.44% |
| Shaily Engineering Plastics Limited | Consumer Cyclical | 1.31% |
| STRIDES PHARMA SCIENCE LIMITED | Healthcare | 1.27% |
| VIJAYA DIAGNOSTIC CENTRE LIMITED | Healthcare | 1.25% |
| KOVAI MEDICAL CENTER & HOSPITAL LIMITED | Healthcare | 1.25% |
| PFIZER LIMITED | Healthcare | 1.24% |
| POLY MEDICURE LIMITED | Healthcare | 1.23% |
| Sector | Holdings | Weight |
|---|---|---|
| Healthcare | 33 | 88.35% |
| Chemicals | — | 3.24% |
| Capital Goods | — | 1.31% |
Active bets vs the average Equity fund. Biggest deviations shown first.
Accent bar = fund's actual sector weight. Vertical black tick = category average for the same sector. Green overlay = overweight, dashed red = underweight. The biggest active bets show first.
How crowded into the same stocks is this fund vs the largest fund in its category?
Category leader = highest-AUM scheme in the same SEBI category. A high overlap-of-weight number means the fund is concentrated into the same names as the leader (crowded); a low one means it's genuinely differentiated.
| P75 |
|---|
| Max |
|---|
| Positive % |
|---|
| 1Y | -1.12% | 7.51% | 14.13% | 24.56% | 33.22% | 97.9% |
Each cell is one year. Q1 = top quartile within the AMFI category for that period. Cell label is the last two digits of the year.
Top-10 weight 45.5% means concentration is in line with most actively-managed Indian equity funds. Effective-N is the inverse Herfindahl index — a measure of "how many positions effectively drive the fund" after weighting. Category: Equity.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
Each row is a back-tested SIP — monthly contribution over the regime's duration, no fees adjustment beyond NAV-baked TER. XIRR is the annualised IRR of those cashflows; Abs return is the absolute cash-on-cash; Max DD is the deepest drawdown experienced mid-investment. Past performance is not indicative of future results.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.
Does the fund get worse as it gets bigger? Each dot is one historical manager-tenure: AUM at tenure-end vs alpha delivered during that tenure.
Correlation is too weak to confirm or rule out capacity-driven alpha decay. Re-evaluate as more manager-tenure data accumulates.
Each dot is one manager-tenure: X = AUM at tenure end, Y = alpha during that tenure. Connecting line in chronological order. Pearson r measures the linear relationship between AUM and alpha across the historical record. n = 5 data points.
| 5Y |
|---|
| Star |
|---|
| UTI Healthcare Fund - Regular Plan - Growth Option | UTI Mutual Fund | ₹1,144 Cr | 2.30% | +25.58% | +13.65% | 3★ |
| SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH | SBI Mutual Fund | ₹4,323 Cr | 1.90% | +24.26% | +15.05% | 3★ |
| Mirae Asset Healthcare Fund -Regular Growth | Mirae Asset Mutual Fund | ₹2,939 Cr | 2.04% | +24.16% | +13.98% | 3★ |
| Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth | Aditya Birla Sun Life Mutual Fund | ₹901 Cr | 2.27% | +22.88% | +12.34% | 3★ |
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | Tata Mutual Fund | ₹1,325 Cr | 2.21% | +21.66% | +13.09% | 3★ |
| DSP Healthcare Fund - Regular Plan - Growth | DSP Mutual Fund | ₹3,142 Cr | 2.12% | +21.24% | +13.81% | 3★ |
| ITI Pharma and Healthcare Fund - Regular Plan - Growth Option | ITI Mutual Fund | ₹230 Cr | 4.84% | +19.12% | — | 3★ |
| Kotak Healthcare Fund - Regular Plan - Growth Option | Kotak Mahindra Mutual Fund | ₹496 Cr | 2.54% | — | — | 2★ |
| PGIM India Healthcare Fund - Regular Plan - Growth Option | PGIM India Mutual Fund | ₹92 Cr | 2.47% | — | — | 1★ |
| BAJAJ FINSERV HEALTHCARE FUND - REGULAR - GROWTH | Bajaj Finserv Mutual Fund | ₹323 Cr | 2.46% | — | — | 1★ |